drugset / Trial / NCT01132807

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

NCT01132807

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started. Comparing results of diagnostic procedures, such as PET scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Timeline

Start
2010-05
Primary completion
2016-02
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Dacarbazine Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Prednisone Other / unclassified Oral
Subject Vinblastine Small molecule Intravenous
Subject procarbazine Small molecule Oral

Indications